• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids
Chem Pharm Bull (Tokyo). 2021;69(12):1141-1159. doi: 10.1248/cpb.c21-00705.ABSTRACTConsiderable efforts have been made on the development of lipid nanoparticles (LNPs) for delivering of nucleic acids in LNP-based medicines, including a first-ever short interfering RNA (siRNA) medicine, Onpattro, and the mRNA vaccines against the coronavirus disease 2019 (COVID-19), which have been approved and are currently in use worldwide. The successful rational design of ionizable cationic lipids was a major breakthrough that dramatically increased delivery efficiency in this field. The LNPs would be expected to be useful as a platform...
Source: Chemical and Pharmaceutical Bulletin - December 2, 2021 Category: Drugs & Pharmacology Authors: Yusuke Sato Source Type: research

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Drug Metab Pharmacokinet. 2021 Oct 10;41:100424. doi: 10.1016/j.dmpk.2021.100424. Online ahead of print.ABSTRACTNucleic acid therapeutics are developing into precise medicines that can manipulate specific genes. However, the development of safe and effective delivery system for the target cells has remained a challenge. Lipid nanoparticles (LNPs) have provided a revolutionary delivery system that can ensure multiple clinical translation of RNA-based candidates. In 2018, Patisiran (Onpattro) was first approved as an LNP-based siRNA drug. In 2020, during the coronavirus disease 2019 (COVID-19) outbreak, LNPs have enabled the...
Source: Drug Metabolism and Pharmacokinetics - November 10, 2021 Category: Drugs & Pharmacology Authors: Yuta Suzuki Hiroshi Ishihara Source Type: research

Pages: 1  2  3  4